MNPR compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

MNPRMonopar Therapeutics

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

MNPRMonopar Therapeutics

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

MNPRMonopar Therapeutics

68.60▼−5.78%· post 68.60

Mkt cap$488.7MRevenue—Revenue—

LLYELI Lilly & Co

1,371.32▼−3.29%· post 1,363.77

ClosedNov 5 '26

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 5 '26

MNPRMonopar Therapeutics

LLYELI Lilly & Co

68.60▼−5.78%post 68.60

Price

1,371.32▼−3.29%post 1,363.77

$488.7M

Mkt cap

$1.3T

—

Revenue

$24.4BQ3 FY26

—

Revenue

$65.2BFY25

MNPR68.60▼−5.78%vsLLY1,371.32▼−3.29%ClosedNov 5 '26

Earnings history

last 4 reports each · paired by recencyMethod ›

MNPR

Reportimpliedrealized× implied

Q2 FY26—▲+0.38%—

May 14 '26—▼−0.73%—

Q1 FY26—▼−0.84%—

Q3 FY25—▲+5.36%—

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedMNPR realized, solidLLY realized, hatchedOne scale, both sides: full bar = 11%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69